The Wall Street Journal Recognizes Zargis Medical with Technology Innovation Award

PRINCETON, N.J., Sept. 11  /PRNewswire-FirstCall/ -- Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE:SI) and a majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), today announced that it was selected as a runner-up in The Wall Street Journal's 2006 Technology Innovation Awards.  The competition honors breakthrough technologies from around the world in several categories.

As published in today's Wall Street Journal, Zargis was selected as a runner-up in the Medical Devices category for Cardioscan(R), the world's first computer-aided stethoscope that aids physicians in identifying and evaluating murmurs and other heart sounds that may be indicative of cardiovascular disease.  In selecting award winners, The Wall Street Journal's panel of judges considered whether the submitted innovations represented breakthroughs from conventional methods, rather than just incremental improvements.

"We are thrilled to have received this recognition from The Wall Street Journal," stated Zargis CEO John Kallassy.  "Despite the fact that the stethoscope has long served as a representative symbol of medicine, it has remained virtually unchanged for almost two hundred years.  By leveraging our state-of-the-art technology to enhance and extend the clinical usefulness of the stethoscope in ways never before imagined, Zargis Medical has brought the age-old practice of assessing heart sounds into the 21st century."

About Zargis Medical Corp.

Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals.  Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE:SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.

About Cardioscan

Zargis has developed Cardioscan, the first and only FDA-authorized computer-assisted medical device designed to support physicians in analyzing heart sounds for the identification of suspected systolic and diastolic murmurs.  Cardioscan is a non-invasive device that is easy to use, portable, and takes just minutes to perform.  The device implements voice-guided protocol and a graphical user interface while maintaining an efficient physician workflow.  Cardioscan provides a summary of findings in terms that are readily understood by physicians and offers an additional range of quantitative auscultatory information that cannot be obtained through listening alone.

For additional information about Zargis or Speedus Corp., visit the following Web sites: http://www.zargis.com/ and http://www.speedus.com/.

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties.  There are a number of important factors that could cause actual results to differ materially from those expressed in any forward- looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts. 

DATASOURCE: Zargis Medical Corp.



CONTACT:  Peter Hodge, 1-888-773-3669, ext. 23, or , for

Zargis Medical Corp.



Web site:  http://www.speedus.com/

http://www.zargis.com/ 

Copyright